Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy

NCT07166302

Status	RECRUITING
Sponsor	Masaryk University
Enrollment	70 participants

Key Eligibility Criteria

Inclusion (4)

- Subjects must understand the nature of the study and must provide signed and dated written informed consent prior to conducting any study-related procedures
- Willing and able to comply with all protocol procedures
- subjects confirmed the daily (and recent) intake od direct anticoagulants in strandard dosing.
- no other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is taken.

Exclusion (2)

- Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject
- other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is recently taken.

Locations (2 total)

University Hospital Brno, Brno, Czech Republic, Czechia
University hospital Brno, Brno, Czech Republic, Czechia